Neoadjuvant carboplatin/taxane (CbT) with or without doxorubicin/cyclophosphamide (AC) in real-world patients with early triple negative breast cancer (TNBC).

Authors: Mary C. Schroeder, Brahmendra Reddy Viyyuri, Dana McDougall, Sneha Deepak Phadke, John A. Charlson, Noel Estrada-Merly, Cole G. Chapman, Joan Marie Neuner

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e23347

Source: Full article

---

Abstract

e23347